Millendo Therapeutics Inc. Stock News

Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST” Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST”

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Millendo T

NEW YORK, April 2, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Cl

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Millendo Therapeutics, Inc. (NASDAQ: MLND) and Tempest Therapeutics, Inc. is fair

The stock price of Millendo Therapeutics Inc (NASDAQ: MLND) fell by over 10% pre-market. This is why it happened.

Millendo Therapeutics Inc (NASDAQ: MLND) has agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction. The combined company will operate under the Tempest Therape

Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Millendo Therapeutics (NASDAQ:MLND) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zac

Zacks Investment Research upgraded shares of Millendo Therapeutics (NASDAQ:MLND) from a hold rating to a buy rating in a report published on Thursday morning, Zacks.com reports. Zacks Investment Resea

Millendo Therapeutics Inc (NASDAQ:MLND) saw a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 755,100 shares, a growth of 34.6% from

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market

Shares of Millendo Therapeutics Inc (NASDAQ:MLND) dropped 3.8% during trading on Wednesday . The company traded as low as $1.96 and last traded at $1.92, approximately 55,363 shares were traded during